Back to Search Start Over

Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.

Authors :
Sanz-Garcia E
Zou J
Avery L
Spreafico A
Waldron J
Goldstein D
Hansen A
Cho BCJ
de Almeida J
Hope A
Hosni A
Hahn E
Perez-Ordonez B
Zhao Z
Smith C
Zheng Y
Singaravelan N
Bratman SV
Siu LL
Source :
Cell death and differentiation [Cell Death Differ] 2024 Apr; Vol. 31 (4), pp. 460-468. Date of Electronic Publication: 2024 Feb 26.
Publication Year :
2024

Abstract

Up to 30% of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) relapse. Molecular residual disease (MRD) detection using multiple assays after definitive therapy has not been reported. In this study, we included patients with LA-HNSCC (stage III Human Papilloma virus (HPV)-positive, III-IVB HPV-negative) treated with curative intent. Plasma was collected pre-treatment, at 4-6 weeks (FU1) and 8-12 weeks (FU2) post-treatment. Circulating tumor DNA (ctDNA) was analyzed using a tumor-informed (RaDaR®) and a tumor-naïve (CAPP-seq) assay. HPV DNA was measured using HPV-sequencing (HPV-seq) and digital PCR (dPCR). A total of 86 plasma samples from 32 patients were analyzed; all patients with at least 1 follow-up sample. Most patients were stage III HPV-positive (50%) and received chemoradiation (78%). No patients had radiological residual disease at FU2. With a median follow-up of 25 months, there were 7 clinical relapses. ctDNA at baseline was detected in 15/17 (88%) by RaDaR and was not associated with recurrence free survival (RFS). Two patients relapsed within a year after definitive therapy and showed MRD at FU2 using RaDaR; detection of ctDNA during follow-up was associated with shorter RFS (p < 0.001). ctDNA detection by CAPP-seq pre-treatment and during follow-up was not associated with RFS (p = 0.09). HPV DNA using HPV-seq or dPCR during follow-up was associated with shorter RFS (p < 0.001). Sensitivity and specificity for MRD at FU2 using RaDaR was 40% and 100% versus 20 and 90.5% using CAPP-seq. Sensitivity and specificity for MRD during follow-up using HPV-seq was 100% and 91.7% versus 50% and 100% using dPCR. In conclusion, HPV DNA and ctDNA can be detected in LA-HNSCC before definitive therapy. The RaDaR assay but not CAPP-seq may detect MRD in patients who relapse within 1 year. HPV-seq may be more sensitive than dPCR for MRD detection.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1476-5403
Volume :
31
Issue :
4
Database :
MEDLINE
Journal :
Cell death and differentiation
Publication Type :
Academic Journal
Accession number :
38409276
Full Text :
https://doi.org/10.1038/s41418-024-01272-y